Laboratoires Pierre Fabre plans to invest 60 million euros each year in the Asia-Pacific region, aiming to double its revenue from these markets by 2032. This investment strategy prioritizes Asian markets over the United States as the French company seeks to amplify its global growth.
In 2025, Pierre Fabre reported 3.2 billion euros in worldwide sales, and the company is targeting an increase in overall revenue to surpass 5 billion euros by 2032. The Asia-Pacific region, excluding China, generated 170 million euros in 2025, while revenue from the dermo-cosmetics business in China was approximately 180 million euros. Chief Executive Eric Ducournau aims to raise revenue, excluding China, to over 300 million euros and nearly double sales within China, utilizing an annual investment that will represent 20 percent of regional income.
Rebalancing Revenue Streams
The company’s current revenue distribution shows 55 percent coming from dermo-cosmetics and 45 percent from pharmaceuticals. Popular brands such as Eau Thermale Avene, Ducray, and A-Derma highlight the consumer skincare segment, while the pharmaceutical division focuses on oncology, rare diseases, and dermatology. Ducournau’s vision includes achieving a balanced 50-50 split between these divisions globally by 2032. Achieving this balance will depend significantly on expanding distribution in Asia, where pharmaceuticals currently account for 35 percent of net sales in the region.
The company is simultaneously enhancing its drug pipeline through external licensing and biotechnology partnerships. The oncology sector has seen growth, increasing from 19 percent of pharmaceutical revenue in 2018 to 41 percent in 2025, with a focus on therapies for colorectal, lung, and melanoma cancers.
Adjusting Production and Clinical Trials
Following supply chain disruptions during the pandemic, Pierre Fabre has decided to establish dedicated manufacturing facilities in the Asia-Pacific region, aiming to produce both consumer products and pharmaceuticals locally instead of relying entirely on European shipments. Additionally, the company plans to shift clinical trials to the region to better align with the local patient demographics, connecting research directly with hospital networks and healthcare professionals in East and Southeast Asia.
The company is currently focusing on eight key markets: mainland China, Japan, South Korea, Australia, Taiwan, Hong Kong, Vietnam, and Singapore.
Market Expansion and Strategy
While many European beauty and pharmaceutical companies prioritize North America for growth, Pierre Fabre is pivoting towards Asia, where demand for dermo-cosmetics is rapidly increasing. This shift will enable the company to channel larger marketing budgets and improve inventory turnover in Southeast Asian retail channels, including pharmacies, department stores, and e-commerce platforms. However, Ducournau acknowledged the challenges of competing with established Japanese and European brands, which could require significant investment to secure retail space amid tight profit margins.
Malaysia has been highlighted as a critical market for future expansion, alongside Vietnam, due to its rapid consumer spending growth in urban areas. As Pierre Fabre develops its footprint in these regions, Singapore will continue to serve as the operational base for its Asia-Pacific activities, housing approximately 60 employees out of 350 regional staff and facilitating oversight of marketing, regulatory, and clinical trial operations.
The company is projecting an annual growth rate of 8 percent across its global operations, with expectations of double-digit growth in the Asia-Pacific region leading up to the 2032 goal.
